Aktiesnakken — September 2010
-
hvis de lykkes med subkutan, så får de fat i mange nye patienter pga den betydeligt bedre behandlingsform
-
omkostningsmæssigt er der enorme fordele i subkutan frem for intravenøs
-
de er jo ikke lykkedes med noget endnu. Det er blot en strategibeslutning
-
husk også på at analytikerne ikke regner med arzerra i RA
-
og da slet ikke i MS
-
haha .- så er det derfor den falder yderligere....
-
Ges flyver da nu
-
jeg skal af med mine 1.000
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind